<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Interferon beta-1a: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Interferon beta-1a: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Interferon beta-1a: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10766" href="/d/html/10766.html" rel="external">see "Interferon beta-1a: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F183458"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Avonex;</li>
<li>Avonex Pen;</li>
<li>Rebif;</li>
<li>Rebif Rebidose;</li>
<li>Rebif Rebidose Titration Pack;</li>
<li>Rebif Titration Pack</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52912106"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Avonex;</li>
<li>Rebif</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F183497"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Interferon</li></ul></div>
<div class="block doa drugH1Div" id="F183461"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="800e2fc1-5444-4538-baf2-520898316bf7">Multiple sclerosis, relapsing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis, relapsing:</b>
<b>Note:</b>
<b>Safety: </b>In high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other appropriate specialists (eg, liver specialists) regarding treatment options before initiating therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31462584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31462584'])">Ref</a></span>). <b>Premedication:</b> Analgesics and/or antipyretics may help decrease flu-like symptoms on treatment days.</p>
<p style="text-indent:-2em;margin-left:2em;">IM (Avonex):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>US labeling:</i> 30 mcg once weekly; to decrease flu-like symptoms, may initiate once-weekly dosing with 7.5 mcg (week 1) then increase dose in increments of 7.5 mcg once weekly (weeks 2 to 4) up to recommended dose (30 mcg once weekly).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i> 30 mcg once weekly; to decrease flu-like symptoms, may initiate once-weekly dosing with 7.5 mcg (week 1) then increase dose in increments of 7.5 mcg once weekly (weeks 2 to 4) or once every 2 weeks (to week 7) up to recommended dose (30 mcg once weekly). In progressive relapsing MS or secondary progressive MS with recurrent neurologic dysfunction may consider increasing to 60 mcg once weekly.</p>
<p style="text-indent:-2em;margin-left:2em;">SubQ (Rebif): Target dose is either 22 or 44 mcg 3 times weekly; doses should be separated by at least 48 hours:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Target dose 44 mcg 3 times weekly: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 8.8 mcg (20% of target dose) 3 times weekly for 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Titration: 22 mcg (50% of target dose) 3 times weekly for 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Target dose: 44 mcg 3 times weekly.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Target dose 22 mcg 3 times weekly:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 4.4 mcg (20% of target dose) 3 times weekly for 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Titration: 11 mcg (50% of target dose) 3 times weekly for 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Target dose: 22 mcg 3 times weekly.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed6ac157-05b8-4826-bf9d-10972323b607">Single demyelinating event</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Single demyelinating event (Canadian labeling [Rebif]; not in US labeling):</b> SubQ:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Target dose 44 mcg 3 times weekly: Note:</b> Analgesics and/or antipyretics prior to and for 24 hours after dosing may help decrease flu-like symptoms:</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 8.8 mcg (20% of target dose) 3 times weekly for 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Titration: 22 mcg (50% of target dose) 3 times weekly for 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Target dose: 44 mcg 3 times weekly.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990090"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50987368"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustment provided in the manufacturer’s labeling; use with caution in patients with active liver disease, alcohol abuse, ALT &gt;2.5 x ULN, or a history of significant liver disease.</p></div>
<div class="block dot drugH1Div" id="F14385978"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Autoimmune disorder development: Consider discontinuing treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Depression or other severe psychiatric symptoms: Consider discontinuing treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatotoxicity:</p>
<p style="text-indent:-2em;margin-left:4em;">ALT &gt;5 x ULN: Temporarily discontinue therapy or consider dose reduction until ALT normalizes, then may consider retitration of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Symptomatic (eg, jaundice): Discontinue immediately.</p>
<p style="text-indent:-2em;margin-left:2em;">Leukopenia: May require temporary discontinuation or dose reduction until resolution.</p>
<p style="text-indent:-2em;margin-left:2em;">Pulmonary arterial hypertension: Discontinue treatment with confirmed diagnosis.</p></div>
<div class="block doe drugH1Div" id="F183462"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F183431"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (Avonex: 8%; Rebif: 20% to 22%), nausea (Avonex: 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (Avonex: 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia (Rebif: 28% to 36%), lymphadenopathy (Rebif: 11% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (Rebif: 20% to 27%), increased serum aspartate aminotransferase (Rebif: 10% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (neutralizing; significance not known; Avonex: 5%; Rebif: 24% to 31%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (Avonex: 3% to 18%; Rebif: 89% to 92%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (Avonex: 24%), chills (Avonex: 19%), depression (Avonex: 18% to 20%), dizziness (Avonex: 14%), fatigue (Rebif: 41%), headache (58% to 70%), pain (Avonex: 23%), rigors (Rebif: 6% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (Rebif: 23% to 25%), myalgia (25% to 29%), skeletal pain (Rebif: 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (Rebif: 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (49% to 59%), sinusitis (Avonex: 14%), upper respiratory tract infection (Avonex: 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (20% to 28%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (5% to 8%), vasodilation (Avonex: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (Avonex: 4%), erythematous rash (Rebif: 5% to 7%), hyperhidrosis (Rebif: 4%), maculopapular rash (Rebif: 4% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Thyroid disease (Rebif: 4% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Toothache (Avonex: 3%), xerostomia (Rebif: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary frequency (Rebif: 7%), urinary incontinence (Rebif: 4%), urine abnormality (Avonex: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (4% to 5%), thrombocytopenia (Rebif: 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia (Rebif: 2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (Avonex: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Bruising at injection site (Avonex: 6%), inflammation at injection site (Avonex: 6%), pain at injection site (Avonex: 8%), tissue necrosis at injection site (Rebif: 1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia (Rebif: 4% to 5%), drowsiness (Rebif: 4% to 5%), hypertonia (Rebif: 6% to 7%), malaise (Rebif: 4% to 5%), migraine (Avonex: 5%), seizure (Avonex: 1%; Rebif: 4% to 5%), suicidal tendencies (Avonex: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (Avonex: 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Dry eye syndrome (Rebif: 1% to 3%), eye disease (Avonex: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (Avonex: 8%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Local: Residual mass at injection site (Avonex)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (all formulations):</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (all formulations):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiomyopathy, heart failure</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, skin rash, Stevens-Johnson syndrome, urticaria, vesicular eruption</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Heavy menstrual bleeding, hyperthyroidism, hypothyroidism</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Uterine hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia, hemolytic-uremic syndrome, immune thrombocytopenia, thrombotic microangiopathy, thrombotic thrombocytopenic purpura</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Autoimmune hepatitis, hepatic failure, hepatic injury, hepatotoxicity (idiosyncratic) (Chalasani 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, orolingual edema</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Abscess at injection site, cellulitis at injection site, swelling at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Psychiatric disturbance (new or worsening, including psychosis), suicidal ideation</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lupus erythematosus</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Retinal artery occlusion, retinal cotton-wool spot, retinal vascular disease, retinal vein occlusion, retinopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, pulmonary hypertension (including pulmonary arterial hypertension) (McGovern 2015; Health Canada Nov. 2, 2016)</p></div>
<div class="block coi drugH1Div" id="F183445"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to natural or recombinant interferon beta, human albumin (albumin-containing formulations only), or any other component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Rebif: Decompensated liver disease.</p></div>
<div class="block war drugH1Div" id="F183428"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis/hypersensitivity reactions: Allergic reactions, including anaphylaxis, have been reported. Some reactions may occur after prolonged use. Discontinue therapy if anaphylaxis or other allergic reactions occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Autoimmune disorders: Autoimmune disorders including idiopathic thrombocytopenia, hyper- and hypothyroidism and rarely autoimmune hepatitis have been reported. Consider discontinuation of treatment if patient develops a new autoimmune disorder.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Pancytopenia (rare), leukopenia, and thrombocytopenia have been reported. Monitor blood counts at 1, 3, and 6 months post therapy initiation and periodically thereafter. Events may recur with rechallenge.</p>
<p style="text-indent:-2em;margin-left:4em;">• Flu-like symptoms: Associated with a high incidence of flu-like adverse effects; use of analgesics and/or antipyretics on treatment days may be helpful.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Rare cases of severe hepatic injury, including cases of hepatic failure requiring transplantation, have been reported in patients receiving interferon beta-1a; risk may be increased by ethanol use or concurrent therapy with hepatotoxic drugs. Some reports indicate symptoms began after 1 to 6 months of treatment. Transaminase elevations may be asymptomatic. Use with caution in patients with active or a history of liver disease, alcohol abuse, or increased serum ALT (&gt;2.5 times ULN) at baseline. Obtain liver function tests at 1, 3, and 6 months post therapy initiation and periodically thereafter. Treatment should be suspended immediately if jaundice or symptoms of hepatic dysfunction occur. Consider dose reductions or temporary discontinuation if ALT &gt;5 times ULN.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: In high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other specialists (eg, liver specialists) regarding treatment options before initiating therapy (AAN [Farez 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Injection-site reactions: Severe injection-site reactions have occurred, including pain, bruising, erythema, edema, mass, cellulitis, abscess, and necrosis. Necrosis may occur at single and multiple sites. Some reactions have occurred ≥2 years after initiation; reactions typically resolve with conservative treatment (antibiotics or surgical intervention may be required). Patient and/or caregiver competency in injection technique should be confirmed and periodically re-evaluated. Do not inject into affected area until completely healed; if multiple lesions occur, discontinue use until they are fully healed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuropsychiatric disorders: Interferons have been associated with psychiatric adverse events (psychosis, depression, suicidal behavior/ideation) in patients with and without previous psychiatric symptoms; use with caution in patients with depression. Patients exhibiting symptoms of depression or other severe psychiatric symptoms should be closely monitored and discontinuation of therapy should be considered.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary effects: Pulmonary arterial hypertension (sometimes requiring hospitalization and one patient requiring a lung transplant) has occurred in patients without other risk factors taking interferon beta products; onset varies and may occur several years after initiation of treatment. Patients with unexplained symptoms (eg, dyspnea, new or worsening fatigue) should be evaluated for pulmonary arterial hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic microangiopathy: Cases of thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS) (some fatal) have been reported (Hunt 2014; Mahe 2013; Rebif Canadian product labeling 2020). Some cases may occur after several years of therapy. Monitor for new onset hypertension, thrombocytopenia, or impaired renal function; discontinuation of therapy and prompt treatment may be necessary if TTP/HUS are confirmed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with preexisting cardiovascular disease. Rare cases of new-onset cardiomyopathy and/or HF have been reported. In a scientific statement from the American Heart Association, interferon has been determined to be an agent that may either cause reversible direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate/major) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment or in those who abuse alcohol.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a history of seizure disorder.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Thyroid abnormalities may develop with use; may worsen pre-existing thyroid conditions. Monitor thyroid function tests every 6 months or as clinically necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic progressive MS: Safety and efficacy have not been established for this use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Albumin: Some formulations contain albumin, which may carry a remote risk of transmitting Creutzfeldt-Jakob or other viral diseases. Interferon beta-1a formulations that contain albumin are contraindicated in albumin-sensitive patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: The packaging (prefilled syringe tip cap) may contain latex.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Avoid live-attenuated vaccines in patients who currently receive or have recently discontinued interferon beta-1a; consider using live-attenuated vaccines only if risk of infection is high and killed vaccines are unavailable (AAN [Farez 2019]).</p></div>
<div class="block foc drugH1Div" id="F183440"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, solution:</p>
<p style="text-indent:-2em;margin-left:4em;">Avonex: 30 mcg/0.5 mL (0.5 mL) [albumin free; contains mouse (murine) and/or hamster protein; prefilled syringe]</p>
<p style="text-indent:-2em;margin-left:4em;">Avonex Pen: 30 mcg/0.5 mL (0.5 mL) [albumin free; contains mouse (murine) and/or hamster protein; prefilled autoinjector]</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, solution [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Rebif: 22 mcg/0.5 mL (0.5 mL), 44 mcg/0.5 mL (0.5 mL) [contains albumin (human), mouse (murine) and/or hamster protein; prefilled syringe]</p>
<p style="text-indent:-2em;margin-left:4em;">Rebif Rebidose: 22 mcg/0.5 mL (0.5 mL), 44 mcg/0.5 mL (0.5 mL) [contains albumin (human), mouse (murine) and/or hamster protein; autoinjector]</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, solution [preservative free, combination package]:</p>
<p style="text-indent:-2em;margin-left:4em;">Rebif Titration Pack: 8.8 mcg/0.2 mL (6s) and 22 mcg/0.5 mL (6s) [contains albumin (human), mouse (murine) and/or hamster protein; prefilled syringe]</p>
<p style="text-indent:-2em;margin-left:4em;">Rebif Rebidose Titration Pack: 8.8 mcg/0.2 mL (6s) and 22 mcg/0.5 mL (6s) [contains albumin (human), mouse (murine) and/or hamster protein; autoinjector]</p></div>
<div class="block geq drugH1Div" id="F183424"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F183447"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Auto-injector Kit</b> (Avonex Pen Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mcg/0.5 mL (per each): $9,919.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Prefilled Syringe Kit</b> (Avonex Prefilled Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mcg/0.5 mL (per each): $9,919.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Rebif Rebidose Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">22 mcg/0.5 mL (per 0.5 mL): $992.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">44 mcg/0.5 mL (per 0.5 mL): $992.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Rebif Rebidose Titration Pack Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6X8.8 &amp; 6X22 mcg (per mL): $2,834.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Rebif Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">22 mcg/0.5 mL (per 0.5 mL): $992.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">44 mcg/0.5 mL (per 0.5 mL): $992.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Rebif Titration Pack Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6X8.8 &amp; 6X22 mcg (per mL): $2,834.53</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F183442"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">The first injection should be administered under the supervision of a health care professional.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Avonex: Administer IM; rotate injection site; do not inject into area where skin is irritated, red, bruised, scarred, or infected. Two hours after injection, examine site for redness, swelling, or tenderness. Discard any unused portion.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Rebif: Administer SubQ at the same time of day on the same 3 days each week (eg, Mon, Wed, Fri), preferably in the late afternoon or evening; doses should be at least 48 hours apart; rotate injection site; do not inject into area where skin is irritated, red, bruised, or scarred. Discard any unused portion.</p></div>
<div class="block meg drugH1Div" id="F7874830"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Avonex: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F103628s5269lbl.pdf%23page%3D22&amp;token=Zu9JTbAJsk%2BMA6UAmYcoAPs9blKdfe305aktcQxXhXZDzknIMT4JUoFDfG%2FDm0aGCEK%2F2%2Fbyt7hNlFl6QGRmsDvCC6ORfyQ7QkG74%2BwoEm7HS8TVrw58o7xDyptcsNO9&amp;TOPIC_ID=8565" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103628s5269lbl.pdf#page=22</a></p>
<p style="text-indent:-2em;margin-left:4em;">Rebif: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F103780s5214lbl.pdf%23page%3D16&amp;token=I0%2BzhbATCgTy%2F3ftZMPASAUbFYF2t6ALpyF1XISJ1UMCHWOPp2kY0ZpUKt6TmkaMjtzHL3iGZpAr%2BKutsLvRIFw9ufik2YVBYdDWf6X68qmpotZAnr71Tvp9Lx49vSEs&amp;TOPIC_ID=8565" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103780s5214lbl.pdf#page=16</a></p></div>
<div class="block use drugH1Div" id="F183441"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>US labeling:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Multiple sclerosis, relapsing: </b>Treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Canadian labeling:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of relapsing forms of MS to decrease the frequency of clinical exacerbations, delay the accumulation of physical disability, reduce the requirement for steroids, reduce the number of hospitalizations, and reduce disease burden</p>
<p style="text-indent:-2em;margin-left:4em;">To decrease the number and volume of active brain lesions, decrease overall disease burden, and delay onset of clinically definite MS in patients who have experienced a single demyelinating event</p></div>
<div class="block mst drugH1Div" id="F183506"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Avonex may be confused with Avelox</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299523"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F183433"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the adverse/toxic effect of Interferons (Beta). Specifically, the risk for lymphopenia may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Interferon Beta-1a may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk for progressive multifocal leukoencephalopathy (PML) may be increased. Interferon Beta-1a may increase the serum concentration of Natalizumab.  Management: Consider alternatives to this combination whenever possible. Combined use may increase the risk for progressive multifocal leukoencephalopathy (PML).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53487315"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">In general, disease-modifying therapies for multiple sclerosis (MS) are stopped prior to a planned pregnancy except in females at high risk of MS activity (AAN [Rae-Grant 2018]). When disease-modifying therapy is needed in females planning a pregnancy (eg, high risk of disease reactivation), interferon beta-1a may be considered until pregnancy is confirmed, and in select cases (eg, female with active disease), use may be continued during pregnancy. Delaying pregnancy is recommended for females with persistent high disease activity (ECTRIMS/EAN [Montalban 2018]).</p></div>
<div class="block pri drugH1Div" id="F183448"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on available data, an increased risk of adverse fetal events has not been observed when exposure occurs during pregnancy (Burkill 2019; Foulds 2010; Nguyen 2019; Richman 2012; Sandberg-Wollheim 2011; Tomczyk 2013).</p>
<p style="text-indent:0em;margin-top:2em;">In general, disease-modifying therapies for multiple sclerosis (MS) are not initiated during pregnancy, except in females at high risk of MS activity (AAN [Rae-Grant 2018]). When disease-modifying therapy is needed in females planning a pregnancy (eg, high risk of disease reactivation), interferon beta-1a may be considered until pregnancy is confirmed, and in select cases (eg, female with active disease), use may be continued during pregnancy (ECTRIMS/EAN [Montalban 2018]).</p></div>
<div class="block brc drugH1Div" id="F183449"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Interferon beta-1a is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Milk samples were obtained from 6 lactating women (6 to 23 months postpartum) receiving Avonex 30 mcg IM once weekly; sampling occurred at intervals for 72 hours after the dose. The highest reported concentration was 179 pg/mL and the relative infant dose was calculated to be &lt;1% of the maternal dose. Adverse events were not observed in the breastfed infant (Hale 2012). In addition, interferon beta does not have a systemic biologic effect if given orally (Fragoso 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Based on its chemical properties, others consider interferon beta compatible with breastfeeding (Almas 2016; Dobson 2019; Fragoso 2018).</p></div>
<div class="block mop drugH1Div" id="F183437"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Thyroid function tests, CBC with differential, complete metabolic panel; symptoms of autoimmune disorders; signs/symptoms of psychiatric disorder (including depression and/or suicidal ideation); signs/symptoms of injection-site reactions; signs/symptoms of new onset/worsening cardiovascular disease; signs/symptoms of thrombotic microangiopathy (new-onset hypertension, thrombocytopenia, renal impairment); assess patients who develop unexplained symptoms (eg, dyspnea, new or worsening fatigue) for pulmonary arterial hypertension; latent infection screening (eg, hepatitis, tuberculosis) in high-risk populations or in countries with high tuberculosis burden (baseline).</p>
<p style="text-indent:-2em;margin-left:2em;">Avonex: Frequency of monitoring for patients receiving Avonex has not been specifically defined; in clinical trials, monitoring was at 6-month intervals.</p>
<p style="text-indent:-2em;margin-left:2em;">Rebif: CBC and liver function testing at 1-, 3-, and 6 months, then periodically thereafter. Thyroid function every 6 months (in patients with pre-existing abnormalities and/or clinical indications).</p></div>
<div class="block pha drugH1Div" id="F183427"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Interferon beta differs from naturally occurring human protein by a single amino acid substitution and the lack of carbohydrate side chains; alters the expression and response to surface antigens and can enhance immune cell activities. Properties of interferon beta that modify biologic responses are mediated by cell surface receptor interactions; mechanism in the treatment of MS is unknown.</p></div>
<div class="block phk drugH1Div" id="F183444"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Avonex: 12 hours (based on biological response markers)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Avonex: 4 days (based on biological response markers)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Avonex: ~19 hours (range: 8-54 hours); Rebif: 69 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Avonex (IM): ~15 hours (range: 6-36 hours); Rebif (SubQ): 16 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F183450"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Rebif</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Blastoferon | Escleroferon | Inmunomas | Rebif | Tuterferon</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Rebif</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bio Manguinhos Betainterferona 1a | Rebif</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif nf</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Blastoferon | Rebif | Rebif multidosis | Valentiferon beta</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Avonex</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Rebif nf</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Avonex</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Rebif</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Rebif</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Rebif</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Rebif</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Rebif</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Rebidose | Rebif | Relibeta</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Rebif</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Relibeta</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebidose | Rebif</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Avonex</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Rebif</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Rebif</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Axuareb | Neurauxa | Rebif | Rebif nf | Xerfelan</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Rebif nf</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Rebif</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Blastoferon | Interferon beta 1a prosalud | Relibeta</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Avonex Pen | Rebif</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Rebif</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Genfaxon | Rebif | Teberif</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Rebif</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Rebif</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Rebif</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Rebif</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Betpherum-1a | Rebif</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Befinfer | Blastoferon</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Avonex | Rebif</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26966579">
<a name="26966579"></a>Almas S, Vance J, Baker T, Hale T. Management of multiple sclerosis in the breastfeeding mother. <i>Mult Scler Int</i>. 2016;2016:6527458. doi: 10.1155/2016/6527458.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/26966579/pubmed" id="26966579" target="_blank">26966579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Avonex.1">
<a name="Avonex.1"></a>Avonex (interferon beta-1a) [prescribing information]. Cambridge, MA: Biogen Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Avonex.2">
<a name="Avonex.2"></a>Avonex (interferon beta-1a) [product monograph]. Toronto, Ontario, Canada: Biogen Canada Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31887199">
<a name="31887199"></a>Burkill S, Vattulainen P, Geissbuehler Y, et al. The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis. <i>PLoS One</i>. 2019;14(12):e0227120. doi:10.1371/journal.pone.0227120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/31887199/pubmed" id="31887199" target="_blank">31887199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice parameters Committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18425915">
<a name="18425915"></a>Clerico M, Faggiano F, Palace J, Rice G, Tintorè M, Durelli L. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. <i>Cochrane Database Syst Rev</i>. 2008;(2):CD005278. doi: 10.1002/14651858.CD005278.pub3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/18425915/pubmed" id="18425915" target="_blank">18425915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146409">
<a name="22146409"></a>Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial [published correction appears in <i>Lancet Neurol</i>. 2012;11(2):125]. <i>Lancet Neurol</i>. 2012;11(1):33-41. doi: 10.1016/S1474-4422(11)70262-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/22146409/pubmed" id="22146409" target="_blank">22146409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28039317">
<a name="28039317"></a>Comi G, De Stefano N, Freedman MS, et al. Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. <i>J Neurol Neurosurg Psychiatry</i>. 2017;88(4):285-294. doi: 10.1136/jnnp-2016-314843.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/28039317/pubmed" id="28039317" target="_blank">28039317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30612100">
<a name="30612100"></a>Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. <i>Pract Neurol</i>. 2019;19(2):106-114. doi: 10.1136/practneurol-2018-002060.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/30612100/pubmed" id="30612100" target="_blank">30612100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31462584">
<a name="31462584"></a>Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2019;93(13):584-594. doi:10.1212/WNL.0000000000008157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/31462584/pubmed" id="31462584" target="_blank">31462584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Foulds.1">
<a name="Foulds.1"></a>Foulds P, Richman S, Glick G, Onigman T, Hyde R. Pregnancy outcomes from the Avonex (interferon beta-1a) pregnancy exposure registry. <i>Mult Scler</i>. 2010;16:S315. https://journals.sagepub.com/doi/pdf/10.1177/1352458510383204.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30167914">
<a name="30167914"></a>Fragoso YD, Adoni T, Brooks JBB, et al. Practical evidence-based recommendations for patients with multiple sclerosis who want to have children. <i>Neurol Ther</i>. 2018;7(2):207-232. doi: 10.1007/s40120-018-0110-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/30167914/pubmed" id="30167914" target="_blank">30167914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21988602">
<a name="21988602"></a>Hale TW, Siddiqui AA, Baker TE. Transfer of Interferon β-1a into Human Breastmilk. <i>Breastfeed Med.</i> 2012;7(2):123-125.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/21988602/pubmed" id="21988602" target="_blank">21988602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HCRA.1">
<a name="HCRA.1"></a>Healthy Canadians Recalls &amp; Alerts. Interferon beta products — assessing the potential risk of pulmonary arterial hypertension. https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00127. Published November 2, 2016. Accessed November 16, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24670186">
<a name="24670186"></a>Hunt D, Kavanagh D, Drummond I, et al. Thrombotic microangiopathy associated with interferon beta. <i>N Engl J Med</i>. 2014;370(13):1270-1271.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/24670186/pubmed" id="24670186" target="_blank">24670186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11006365">
<a name="11006365"></a>Jacobs LD, Beck RW, Simon JH, et al. Intramuscular Interferon Beta-1a Therapy Initiated During a First Demyelinating Event in Multiple Sclerosis. CHAMPS Study Group. <i>N Engl J Med.</i> 2000;343(13):898-904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/11006365/pubmed" id="11006365" target="_blank">11006365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23950639">
<a name="23950639"></a>Mahe J, Meurette A, Moreau A, et al. Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis. <i>Drug Des Devel Ther</i>. 2013;7:723-728.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/23950639/pubmed" id="23950639" target="_blank">23950639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26008947">
<a name="26008947"></a>McGovern EM, Judge EP, Kavanagh E, Gaine S, Lynch T. Interferon beta related pulmonary arterial hypertension; an emerging worrying entity? <i>Mult Scler Relat Disord</i>. 2015;4(3):284-286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/26008947/pubmed" id="26008947" target="_blank">26008947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29352526">
<a name="29352526"></a>Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis [published correction appears in <i>Eur J Neurol</i>. 2018;25(3):605]. <i>Eur J Neurol</i>. 2018;25(2):215-237. doi: 10.1111/ene.13536.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/29352526/pubmed" id="29352526" target="_blank">29352526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. Updated October 9, 2020. Available at: <a href="https://covid19treatmentguidelines.nih.gov/" target="_blank">https://covid19treatmentguidelines.nih.gov/</a>. Accessed October 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30623864">
<a name="30623864"></a>Nguyen AL, Havrdova EK, Horakova D, et al; MSBase Study Group. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort study. <i>Mult Scler Relat Disord</i>. 2019;28:235‐243. doi:10.1016/j.msard.2019.01.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/30623864/pubmed" id="30623864" target="_blank">30623864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12451188">
<a name="12451188"></a>Panitch H, Goodin DS, Francis G, et al, “Randomized, Comparative Study of Interferon Beta-1a Treatment Regimens in MS: The EVIDENCE Trial. EVIDENCE Study Group. Evidence of Interferon Dose-Response: European North American Comparative Efficacy; University of British Columbia MS/MRI Research Group,” <i>Neurology</i>, 2002, 59(10):1496-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/12451188/pubmed" id="12451188" target="_blank">12451188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rae-Grant.1">
<a name="Rae-Grant.1"></a>Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. https://download.lww.com/wolterskluwer_vitalstream_com/PermaLink/WNL/A/WNL_2018_04_19_RAEGRANT_NEUROLOGY2017835181R1_SDC3.pdf. Published April 2018. Accessed January 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rebif.1">
<a name="Rebif.1"></a>Rebif (interferon beta-1a) [prescribing information]. Rockland, MA: EMD Serono Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rebif.2">
<a name="Rebif.2"></a>Rebif (interferon beta-1a) [product monograph]. Mississauga, Ontario, Canada: EMD Serono; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Richman.1">
<a name="Richman.1"></a>Richman S, Wallace K, Liu S, Sperling B. Final results from the AVONEX® (intramuscular interferon beta-1a) pregnancy exposure registry (P06.191). <i>Neurology.</i> 2012;78 (meeting abstracts 1):P06.191.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21220368">
<a name="21220368"></a>Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. <i>Mult Scler</i>. 2011;17(4):423‐430. doi:10.1177/1352458510394610<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1a-drug-information/abstract-text/21220368/pubmed" id="21220368" target="_blank">21220368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tomczyk.1">
<a name="Tomczyk.1"></a>Tomczyk S, Sperling B. Pregnancy Outcomes in Patients Exposed to Intramuscular Interferon Beta-1a (IM IFNβ-1a). <i>Neurology.</i> 2013;80(7 suppl):S30.006.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8565 Version 206.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
